Sarepta Therapeutics Inc.

News & Events

Press Releases

In The Media

1. SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

   NewMediaWire MAY 22, 2025 5:04 PM EDT
   RADNOR, PA - May 22, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, ...
   READ ARTICLE

2. Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

   Business Wire MAY 21, 2025 8:30 AM EDT
   Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare disea...
   READ ARTICLE

3. Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

   Business Wire MAY 16, 2025 9:01 AM EDT
   - Treatment with ELEVIDYS for Duchenne muscular dystrophy resulted in mean protein expression...
   READ ARTICLE

4. Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

   Business Wire MAY 16, 2025 9:00 AM EDT
   Significant functional benefits for 8- and 9-year-olds with Duchenne in Part 2 of the EMBARK stud...
   READ ARTICLE

5. SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

   NewMediaWire MAY 14, 2025 5:01 PM EDT
   RADNOR, PA - May 14, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, ...
   READ ARTICLE

6. Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

   Business Wire MAY 13, 2025 9:25 AM EDT
   Approval based on efficacy and safety results from clinical studies, including longer-term functi...
   READ ARTICLE

7. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

   GlobeNewswire MAY 9, 2025 10:15 AM EDT
   NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inv...
   READ ARTICLE

8. SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

   NewMediaWire MAY 9, 2025 9:36 AM EDT
   RADNOR, PA - May 9, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, L...
   READ ARTICLE

9. Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

   Business Wire MAY 8, 2025 4:30 PM EDT
   Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare disea...
   READ ARTICLE

10. SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

    NewMediaWire MAY 8, 2025 10:04 AM EDT
    RADNOR, PA - May 8, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, L...
    READ ARTICLE